January 15, 2021
A key health ministry advisory panel will discuss on January 27 whether to approve the label expansion of Fujimoto Pharmaceutical’s Thaled (thalidomide) into POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome. The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC)...read more